reverse-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
=== Baking === Powdered milk is often used in confectionery such as chocolate and caramel candy and in recipes for baked goods where adding liquid milk would render the product too thin. Powdered milk is also widely used in various sweets such as the Indian milk balls known as gulab jamun and the popular Indian sweet known as chum chum (made with skim milk powder, sprinkled with desiccated coconut). Many no-cook recipes that use nut butters use powdered milk to prevent the nut butter from turning liquid by absorbing the oil. Due to the Maillard reaction, cooking powdered milk can lend it a caramelized, toasty flavor which is desirable in baked goods. Bon Appétit editor Shilpa Uskokovic also notes that the extra sugars and fats present in powdered milk can add additional caramelization to brown butter, render ice cream creamier and yogurt thicker, and "[improve] the structure and texture of yeast breads, making them loftier and more tender."
Sarcoidosis, amyloidosis, and Whipple's disease can also resemble RA. Hemochromatosis may cause hand joint arthritis. Acute rheumatic fever can be differentiated by a migratory pattern of joint involvement and evidence of antecedent streptococcal infection. Bacterial arthritis (such as by Streptococcus) is usually asymmetric, while RA usually involves both sides of the body symmetrically. Gonococcal arthritis (a bacterial arthritis) is also initially migratory and can involve tendons around the wrists and ankles. Sometimes arthritis is in an undifferentiated stage (i.e., none of the above criteria is positive), even if synovitis is witnessed and assessed with ultrasound imaging.
== Applications == One of the potent applications of siRNAs is the ability to distinguish the target versus non-target sequence with a single-nucleotide difference. This approach has been considered therapeutically crucial for silencing dominant gain-of-function (GOF) disorders, where the mutant allele causing disease differs from the wild-type allele by a single nucleotide (nt). These types of siRNAs, which are capable of distinguishing a single-nucleotide difference, are termed allele-specific siRNAs. ASP-RNAi is an innovative category of RNAi with the objective of suppressing the dominant mutant allele while sparing expression of the corresponding normal allele with the specificity of single-nucleotide differences between the two. ASP-siRNAs are potentially a novel and better remedial alternative for the treatment of autosomal dominant genetic disorders, especially in cases where wild-type allele expression is crucial for organism survival, such as Huntington disease (HD), DYT1 dystonia (Gonzalez-Alegre et al. 2003, 2005), Alzheimer's disease (AD) (Sierant et al. 2011), Parkinson's disease (PD) (Takahashi et al. 2015), amyotrophic lateral sclerosis (ALS) (Schwarz et al. 2006), and Machado-Joseph disease (MJD) (Alves et al. 2008). Their therapeutic potential has also been assessed for various skin disorders like epidermolysis bullosa simplex (Atkinson et al. 2011), epidermolytic palmoplantar keratoderma (EPPK) (Lyu et al. 2016), and lattice corneal dystrophy type I (LCDI) (Courtney et al. 2014).
== Early political career (1959–1970) == After World War II ended and the Japanese withdrew, the British grouped the Malay states and the Straits Settlements into the Malayan Union, and granted citizenship to non-Malays. This caused major backlash from Malays and a wave of Malay nationalism swept across the country. Mahathir became politically activated by these changes, joining protests and activism against the new citizenship policies. Mahathir later argued for affirmative action for Malays at medical college. While at college, he contributed to The Straits Times under the pseudonym "C.H.E. Det" and a student journal, in which he fiercely promoted Malay rights, such as calling for the restoration of Malay as an official language. While practising as a physician in Alor Setar, Mahathir became active in UMNO. His earliest political involvement was in the Kampung Charok Kudong Umno branch, where he made his debut in politics. By the time of the first general election for the independent state of Malaya in 1959, he was the chairman of the party in Kedah. Despite his prominence in UMNO, Mahathir was not a candidate in the 1959 election, ruling himself out following a disagreement with then Prime Minister Tunku Abdul Rahman. Their relationship had been strained since Mahathir had criticised Tunku's agreement to retain British and Commonwealth forces in Malaya after independence. Tunku opposed Mahathir's plans to introduce minimum educational qualifications for UMNO candidates.
==== Pulmonary tissues ==== Lung tissue engineering focuses on developing functional respiratory structures to treat end-stage pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and acute respiratory distress syndrome (ARDS). Due to the complex, highly vascularized three-dimensional architecture of the lung, which comprises over forty distinct cell types and a delicate alveolar-capillary basement membrane, whole-organ biofabrication typically relies on decellularized donor lung scaffolds. This process strips away immunogenic cellular material while preserving the native extracellular matrix geometry and mechanical compliance required for ventilation. Research strategies prioritize the multi-lineage recellularization of these scaffolds using patient-specific induced pluripotent stem cells (iPSCs) differentiated into alveolar epithelial cells (type I and II) and microvascular endothelial cells. Additionally, biomimetic microfluidic platforms, or "lung-on-a-chip" models, are utilized to study cellular shear stress and gas-exchange dynamics, serving as precursors to transplantable bioartificial lung devices.
Sources: en.wikipedia.org
== Sources of exposure == Smoking is a significant source of cadmium exposure. Even small amounts of cadmium from smoking are highly toxic to humans, as the lungs absorb cadmium more efficiently than the stomach. Cadmium is emitted to the electronic cigarette (EC) aerosol but, on currently available data, the lifetime cancer risk (LCR) calculated does not exceed the acceptable risk limit.
As with bacterial classification, identification of bacteria is increasingly using molecular methods, and mass spectroscopy. Most bacteria have not been characterised and there are many species that cannot be grown in the laboratory. Diagnostics using DNA-based tools, such as polymerase chain reaction, are increasingly popular due to their specificity and speed, compared to culture-based methods. These methods also allow the detection and identification of "viable but nonculturable" cells that are metabolically active but non-dividing. The main way to characterize and classify these bacteria is to isolate their DNA from environmental samples and mass-sequence them. This approach has identified thousands, if not millions of candidate species. Based on some estimates, more than 43,000 species of bacteria have been described, but attempts to estimate the true number of bacterial diversity have ranged from 107 to 109 total species—and even these diverse estimates may be off by many orders of magnitude.
The ligated mRNA-DNA-puromycin library is translated in Red Nova Lysate (Novagen) or E. coli S30 Extract System (Promega), resulting in peptides covalently linked in cis to the encoding mRNA. The in vitro translation can also be done in a PURE (protein synthesis using recombinant elements) system. PURE system is an E. coli cell-free translation system in which only essential translation components are present. Some components, such as amino acids and aminoacyl-tRNA synthases (AARSs) can be omitted from the system. Instead, chemically acylated tRNA can be added into the PURE system. It has been shown that some unnatural amino acids, such as N-methyl-amino acid accylated tRNA can be incorporated into peptides or mRNA-peptide fusions in a PURE system. After translation, the single-stranded mRNA portions of the fusions will be converted to heteroduplex of RNA/DNA by reverse transcriptase to eliminate any unwanted RNA secondary structures, and render the nucleic acid portion of the fusion more stable. This step is a standard reverse transcription reaction. For instance, it can be done by using Superscript II (GIBCO-BRL) following the manufacturer's protocol.
== Further information == Thorium, from which 233U is bred, is roughly three to four times more abundant in the Earth's crust than uranium. The decay chain of 233U itself is part of the neptunium series, the decay chain of its grandparent 237Np. Uses for uranium-233 include the production of the medical isotopes actinium-225 and bismuth-213 which are among its daughters, low-mass nuclear reactors for space travel applications, use as an isotopic tracer, nuclear weapons research, and reactor fuel research including the thorium fuel cycle. Bismuth-213 has been investigated for use in cancer treatment. However, producing the medical isotopes from 233U practically requires separating the long-lived intermediate thorium-229. At Oak Ridge, thorium-229 is recovered from stored uranium-233 and supplied to TerraPower Isotopes for the production of actinium-225 used in cancer-treatment research.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.